This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pacira (PCRX) Gets Positive CHMP View on Exparel Label Expansion
by Zacks Equity Research
The CHMP gives a positive opinion on Pacira's (PCRX) marketed drug Exparel and recommended a marketing authorization for the product to treat postsurgical pain in children aged six years or older.
Pacira (PCRX) Up on Data From Exparel Label Expansion Study
by Zacks Equity Research
Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.
Why Is Pacira (PCRX) Down 9.2% Since Last Earnings Report?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.
Pacira (PCRX) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of -37.04% and 0.06%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) second-quarter earnings call, investors are expected to focus on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Pacira (PCRX) Up 2.1% Since Last Earnings Report?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.
Pacira (PCRX) Q1 Earnings Miss Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of -13.51% and 0.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Pacira (PCRX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pacira (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What to Expect From Centene (CNC) this Earnings Season?
by Zacks Equity Research
Centene's (CNC) first-quarter results are likely to reflect growing revenues attributable to a rise in premiums and membership, partly offset by lower investment income.
Here's Why Pacira (PCRX) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pacira (PCRX) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pacira (PCRX) Rides High in YTD Period on Robust Exparel Sales
by Zacks Equity Research
Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.
Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.
Pacira (PCRX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 16.87% and 0.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Pacira (PCRX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InMed Pharmaceuticals Inc. (INM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -29.17% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Community Health (CYH) Unit Declares Pricing of Senior Notes
by Zacks Equity Research
Community Health's (CYH) wholly-owned arm exhibits monetary discretion by pricing senior notes to procure funds.
The Zacks Analyst Blog Highlights: Pacira BioSciences, D.R. Horton ArcBest, Axis Capital Holdings and CF Industries
by Zacks Equity Research
Pacira BioSciences, D.R. Horton ArcBest, Axis Capital Holdings and CF Industries are highlighted in this Analyst Blog Article.